Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03MZJ
|
||||
| Former ID |
DNC004894
|
||||
| Drug Name |
BUCINDOLOL
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H25N3O2
|
||||
| Canonical SMILES |
CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
|
||||
| InChI |
1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
|
||||
| InChIKey |
FBMYKMYQHCBIGU-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 71119-11-4
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta-2 adrenergic receptor | Target Info | Modulator | ||
| Beta-1 adrenergic receptor | Target Info | Modulator | |||
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Salivary secretionhsa04020:Calcium signaling pathway | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta2 adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Beta1 adrenergic receptor signaling pathway | |||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| Arf6 signaling events | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling eventsR-HSA-390696:Adrenoceptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Vitamin D Receptor Pathway | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP58:Monoamine GPCRs | |||||
| Endothelin Pathways | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01970501) Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.